Improved efficacy and tolerability of oral deferasirox by twice‐daily dosing for patients with transfusion‐dependent β‐thalassemia

Abstract

Twice-daily deferasirox dosing is effective in iron chelation and improves tolerability in transfusion-dependent β-thalassemia patients who are unresponsive to or intolerant of once-daily deferasirox. Future studies with greater patient numbers will be required to confirm the results reported herein.